ライフサイエンスコーパス: small lymphocytic lymphoma

1 sly treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.

2 eatment-naive and relapsed/refractory CLL or small lymphocytic lymphoma.

3 lymphocytic leukaemia and two patients with small lymphocytic lymphoma.

4 patients with relapsed or refractory CLL or small lymphocytic lymphoma.

5 le exception of chronic lymphocytic leukemia/small lymphocytic lymphoma.

6 (P = 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma.

7 oma, and B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.

8 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.

9 0.4, 0.4, 0.3; p trend = 0.03) with risk of small lymphocytic lymphoma.

10 with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.

11 arge B-cell and chronic lymphocytic leukemia/small lymphocytic lymphomas.

12 sed B-cell lymphomas, such as follicular and small lymphocytic lymphomas.

13 non-Hodgkin's lymphomas, including cases of small lymphocytic lymphoma (18 cases), marginal zone lym

14 included follicular lymphoma (72 patients), small lymphocytic lymphoma (28), marginal-zone lymphoma

15 ne and zinc finger domains (TRAF2DN) develop small lymphocytic lymphoma and chronic lymphocytic leuke

16 ciation between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.

17 lymphoma (137 diffuse, 58 follicular, and 32 small lymphocytic lymphomas) and 63 cases of B-CLL were

18 ), and group C (chronic lymphocytic leukemia/small lymphocytic lymphoma, and other indolent lymphomas

19 lent lymphomas (6 marginal zone lymphomas, 7 small lymphocytic lymphomas, and 13 follicular lymphomas

20 The large lymphoid cells in small lymphocytic lymphoma are also rich in hsp89, but n

21 s transplantation was found to have stage IV small lymphocytic lymphoma at the time of transplantatio

22 inal zone lymphoma (MZL), MALT lymphoma or B-small lymphocytic lymphoma (B-SLL) cell lines or patient

23 r lymphoma (Case 1), follicular lymphoma and small lymphocytic lymphoma (Case 2), and mantle cell lym

24 ll lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (Case 3).

25 with risk of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL).

26 luding 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other

27 mphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) but not for other N

28 hereas rates of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) declined 2.1% per y

29 analysis, RR of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was 1.66 (95% CI, 1

30 dicated that chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) was the principal N

31 data exist for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

32 ed frequency in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

33 5.41), but not chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; HR, 0.84; 95% CI, 0

34 (N = 106), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; N = 133).

35 kemias, such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 15), mantle cel

36 tic lymphomas, 2 follicular lymphomas, 4 CLL/small lymphocytic lymphomas (CLL/SLLs), and 1 low-grade

37 of 39 cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (diffusely positive in 33 cas

38 For patients with small lymphocytic lymphoma, dosing began at 10 mg/day to

39 omas, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and man

40 d in 8 patients with relapsed/refractory CLL/small lymphocytic lymphoma harboring ATM deletions/mutat

41 in contrast to follicle center lymphoma and small lymphocytic lymphoma; however, pRB expression does

42 Interfollicular small lymphocytic lymphoma (I-SLL) has not been well cha

43 -2 in promoting chronic lymphocytic leukemia/small lymphocytic lymphoma in mice, possibly by specific

44 patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high

45 ymptomatic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is encouraging, and merits fu

46 center B cells (chronic lymphocytic leukemia/small lymphocytic lymphomas, mantle cell lymphomas, and

47 One patient with transformed small lymphocytic lymphoma met criteria for complete res

48 phoma (n = 3), mantle cell lymphoma (n = 2), small lymphocytic lymphoma (n = 2), and myeloid leukemia

49 zone (n = 4), lymphoplasmacytic (n = 1), or small lymphocytic lymphoma (n = 3); and CLL (n = 11), we

50 a (n=50), marginal zone lymphoma (n=30), and small lymphocytic lymphoma (n=30) were enrolled from Jun

51 Low-grade, small lymphocytic lymphomas of the mucosa-associated lym

52 None of the B-cell small lymphocytic lymphomas or mantle cell lymphomas exp

53 nib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for

54 y activation in chronic lymphocytic leukemia/small lymphocytic lymphoma, plasma cell myeloma, mantle

55 ated del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma received oral ibrutinib 420 m

56 tients with chronic lymphocytic leukaemia or small lymphocytic lymphoma relapse after initial therapy

57 1.16, 1.96) and chronic lymphocytic leukemia/small lymphocytic lymphoma (relative risk = 1.93, 95% co

58 symptomatic chronic lymphocytic leukaemia or small lymphocytic lymphoma requiring therapy.

59 homa grade 1 or 2, and 22% (four of 18) with small lymphocytic lymphoma responded to therapy.

60 0.17-0.78) and chronic lymphocytic leukemia/small lymphocytic lymphoma (RR, 0.46; 95% CI, 0.21-1.01)

61 d or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of

62 Of 30 evaluable patients with small lymphocytic lymphoma, seven (23%) had a complete r

63 Small lymphocytic lymphoma showed minimal TG staining, w

64 included eight chronic lymphocytic leukemia/small lymphocytic lymphomas, six mantle cell lymphomas,

65 Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considere

66 d follicular lymphoma, 11 had MCL, three had small lymphocytic lymphoma (SLL) or chronic lymphocytic

67 n well characterized and its relationship to small lymphocytic lymphoma (SLL) or chronic lymphocytic

68 The effect was most pronounced for the CLL/small lymphocytic lymphoma (SLL) subtype (OR: 1.0; 3.2 [

69 ents with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that was maintained at

70 patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharm

71 ents with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The Un

72 ents with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of re

73 sed in non-Hodgkin's lymphoma (NHL), such as small lymphocytic lymphoma (SLL), and many other cancers

74 Patients with CLL/small lymphocytic lymphoma (SLL), prolymphocytic leukemi

75 come was compared with that of patients with small lymphocytic lymphoma (SLL)/B-cell chronic lymphocy

76 has been reported to have little activity in small lymphocytic lymphoma (SLL)/chronic lymphocytic leu

77 lymphomas (FL), three transformed FLs, four small lymphocytic lymphomas (SLL), two Waldenstrom's mac

78 f 237 tumors (10.5%), which included 1 of 45 small lymphocytic lymphomas (SLLs), 2 of 38 follicular s

79 the risk of the chronic lymphocytic leukemia/small lymphocytic lymphoma subtype among women only (253

80 For chronic lymphocytic leukemia/small lymphocytic lymphoma, suggestive associations were

81 pposite associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance

82 International Workshop on CLL guidelines) or small lymphocytic lymphoma were eligible for this phase

83 ed were CPP32 immunopositive, whereas 3 of 3 small lymphocytic lymphomas were CPP32 negative, suggest

84 with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma who received at least one dos

85 had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with measurable lymph node di